Home / Production Assistant, Diabetes In Control (page 6)

Production Assistant, Diabetes In Control

Cannabis-Based Medicine

A recent Cochrane Review found which one of the following to be true about the effects of cannabis-based medicines on neuropathic pain?

A. All cannabis-based medicines (herbal, plant-derived, synthetic) pooled together were more effective than placebo for pain relief.
B. Herbal cannabis medicines were more effective than placebo for pain relief.
C. There was a high level of evidence that cannabis-based medicines were more effective than placebo for pain relief.
D. All of the above are true.
E. None of the above is true.

Follow the link for the answer.

Read More »

Samples Are Not the Answer

adding an sglt2 inhibitor to insulin

A woman, 72 years of age was recently diagnosed with type 2 diabetes. She has a Medicare plan. I don’t know her financial situation but do know she gets Social Security and has other retirement income. Her A1C was rising. We had recommended and taught lifestyle changes which she had difficulty with; she made some changes but not enough to lower her glucose. We added metformin which she did not tolerate, so we discussed one of the SGLT-2s. After hesitating, she agreed to trying one. We gave her samples, she took them. Her A1C lowered to the goal we mutually decided upon.

Read More »

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #165: Molecular Genetics of Type 1 Diabetes Part 2

HLA-DR and -DQ: The highest risk of T1DM is conferred by heterozygosity for the DRB1*0301-DQA1*0501-DQB1*0201 and DRB1*04-DQA1* 0301-DQB1*0302 haplotypes, referred to as the DR3.DQ2/DR4.DQ8 genotype. This allelic combination is carried by 30–40% of individuals with T1DM, but only around 2.5% of the general population [3]. A recent meta-analysis of multiple ethnic groups suggested that this translates into an OR value greater than 16, an unusually large odds ratio for a complex disease [14]. This is consistent with an earlier study which estimated that the risk of developing T1DM was between 1 in 15 and 1 in 25 among those with the DR3.DQ2/DR4.DQ8 genotype, compared with 1 in 300 in the general population [15]. High risk is also conferred by the DR3.DQ2/DR3.DQ2 and DR4.DQ8/DR4.DQ8 homozygous genotypes (OR = 6.32 and OR = 5.68, respectively, from meta-analysis).

Read More »